SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Table 13 Change in homeostasis model assessment-estimated insulin resistance in individual studies

Study	HOMA-IR			P value	P value between groups
	Group	Baseline	Study completion
Ito et al[12]	Ipragliflozin	5.2 (2.5)	4.8 (5.5)	Non-significant	0.401
	Pioglitazone	5.7 (3.4)	4.5 (2.7)	< 0.05
Eriksson et al[14]	Placebo	4.2 (2.4)	-0.2 (1.4)1	-	-
	Omega 3-CA	5.4 (2.9)	+0.3 (2.4)1	-	Non-significant2
	Dapagliflozin	4.3 (1.9)	-1.1 (1.4)1	-	< 0.052
	O + D	4.4 (1.7)	-0.9 (1.6)1	-	< 0.052
Seko et al[16]	SGLT-2 inhibitor	4.5 (0.5)	7.9 (2.3)	0.955	-
	Sitagliptin	4.4 (0.5)	6.5 (0.8)	0.163

¹Change from baseline.

² Compared to placebo.

HOMA-IR: Homeostasis model assessment-estimated insulin resistance; CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.